Sign In
Buy RVTY
$101.07
+0.680 (+0.677%)
At Close: Jun 03, 2026
Will RVTY Q3 Earnings Reflect Segmental Strength Amid Rising Demand?
08:55am, Thursday, 23'rd Oct 2025
RVTY's third-quarter results are likely to reflect strong performance in the Life Sciences segment. However, the Diagnostic segment is set to face challenges in China.
Revvity (RVTY) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
10:16am, Wednesday, 22'nd Oct 2025
Get a deeper insight into the potential performance of Revvity (RVTY) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for s
Analysts Estimate Revvity (RVTY) to Report a Decline in Earnings: What to Look Out for
11:00am, Monday, 20'th Oct 2025
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revvity Showcases Progress with Purpose in 2025 Impact Report
08:00am, Tuesday, 14'th Oct 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today released its annual Impact Report, a comprehensive reflection of the Company's sustainability, social and governance strategy, initi
RVTY Collaborates With Sanofi for Early Detection of Type 1 Diabetes
12:55pm, Thursday, 09'th Oct 2025
Revvity partners with Sanofi to launch a scalable diagnostic test for early T1D detection, expanding its reach beyond rare diseases.
Revvity to Hold Earnings Call on Monday, October 27, 2025
08:00am, Monday, 06'th Oct 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2025 financial results prior to market open on Monday, October 27, 2025. The Company
Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes
08:00am, Thursday, 02'nd Oct 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with s
Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis
08:00am, Monday, 29'th Sep 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Today Revvity, Inc. (NYSE: RVTY), announced the launch of its Living Image™ Synergy AI multimodal analysis software for in vivo imaging researchers. The solution pro
Revvity and Profluent Collaborate to Launch AI-Enhanced Adenine Deaminase Pin-point Base Editing Systems
08:00am, Monday, 22'nd Sep 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced a strategic collaboration with Profluent, bringing together a range of its novel AI-engineered enzymes with Revvity's established
Revvity, Inc. (RVTY) Presents At Baird 2025 Global Healthcare Conference (Transcript)
05:31pm, Tuesday, 09'th Sep 2025
Revvity, Inc. (NYSE:RVTY ) Baird 2025 Global Healthcare Conference September 9, 2025 2:35 PM EDT Company Participants Stephen Willoughby - Senior VP of Investor Relations & Head of ESG Conference Call
Revvity, Inc. (RVTY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
10:40am, Wednesday, 03'rd Sep 2025
Revvity, Inc. (NYSE:RVTY ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 8:00 AM EDT Company Participants Maxwell Krakowiak - Senior VP & CFO Conference Call Participants Brando
Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina
08:00am, Tuesday, 02'nd Sep 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the opening of its new In Vivo Imaging Center of Excellence in Morrisville, North Carolina, the heart of the state's Resear
Revvity to Present at Upcoming Investor Conferences
08:00am, Monday, 18'th Aug 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: 2025 Wells Fargo Healthcare Conference Wednesday, September 3, 2025
Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics
08:00am, Wednesday, 06'th Aug 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of pHSense™ reagents, a powerful technology designed to advance internalization studies in drug discovery. pHS
Revvity Q2: Headwinds From China And Customers, Buy On Weakness
02:47pm, Monday, 28'th Jul 2025
Revvity, Inc.'s focus on high-growth markets like cell and gene therapies and precision medicine positions it for long-term expansion despite near-term challenges. The recent divestiture streamlines R
